BiotechTV

𝐅𝐫𝐨𝐦 𝐒𝐞𝐚𝐭𝐭𝐥𝐞: Seal Rock Therapeutics is working on a second-generation ASK1 inhibitor that is designed to improve on the safety profile of the class and could have utility in a range of liver diseases. Co-founder and CEO Neil McDonnell describes the history of ASK1 and how Seal Rock's program has been optimized to avoid roadblocks that pharma companies experienced in the past. He explains how the company is currently putting it to use in cirrhosis, liver failure (with partner Genfit), and in CNS conditions (along with LRRK2). Full video: https://lnkd.in/ga6fRQfQ BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐅𝐫𝐨𝐦 𝐒𝐞𝐚𝐭𝐭𝐥𝐞: Nautilus Biotechnology is developing a platform that aims to revolutionize how researchers are able to see the proteome. CEO Sujal Patel tells us how it will work. He describes the shortcomings of high affinity assays and mass spectometry, and how the Nautilus system will be different. Plus, use cases, including recent work on the tau protein he says has caught the attention of drug developers. The device is scheduled to be commercially available approximately late next year. Full video: https://lnkd.in/gE7zfyAZ BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐅𝐫𝐨𝐦 𝐒𝐞𝐚𝐭𝐭𝐥𝐞: Lumen Bioscience is using the cyanobacteria spirulina to manufacture medicines, which might increase the yield and lower the cost of biologics. Its pipeline includes an obesity program. CEO Brian Finrow describes the characteristics of spirulina that Lumen believes will make it the next new paradigm in developing and manufacturing protein-based medicines. He then walks us through the company’s development plans. Full video: https://lnkd.in/gvhyn7XV BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐁𝐢𝐨𝐭𝐞𝐜𝐡 𝐂𝐄𝐎 𝐒𝐢𝐬𝐭𝐞𝐫𝐡𝐨𝐨𝐝: Melinta Therapeutics' CEO Christine Ann Miller on expanding the company into the acute care business, improving employee satisfaction, and her leadership principles. Interviewed by Sisterhood editorial board member Grace Colón, Christine Miller describes taking the job at Melinta after a business reorganization and in the middle of the pandemic, and where and how she has led the business since. Plus, the importance of investing in the antimicrobial space. Full video: https://lnkd.in/gEWMK7_g BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐅𝐫𝐨𝐦 𝐒𝐞𝐚𝐭𝐭𝐥𝐞: Seattle based Umoja Biopharma is a pioneer of in vivo CAR-T cell engineering. CEO Andy Scharenberg describes the technical innovations they have come up with to help make it succeed. Umoja is the first company to have an IND cleared for an in vivo program in the United States. Full video: https://lnkd.in/g-xN5ddB BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

Congratulations to BiotechTV's partner Breakthrough Properties on winning Commercial Observer's 'Breakthrough Award - Life Sciences Transaction of the Year' for the landmark Pfizer Oncology lease at Torrey View in San Diego. I've toured life sciences campuses around the world and I've never seen anything like Torrey View. It's a new class of its own and truly the future of what a life sciences community looks like.

𝐂𝐨𝐨𝐥 𝐓𝐞𝐜𝐡: At an Innovation Day event hosted by Illumina today in La Jolla, CA, BiotechTV got a look at the new MiSeq i100 series of benchtop sequencers. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐀𝐒𝐇 𝟐𝟎𝟐𝟒: France's MaaT Pharma presented early access data at #ASH24 for its microbiome based treatment for GvHD - a formal study will read out early next year. CMO Gianfranco Pittari, MD PhD describes the unmet neet in GvHD and how the donor derived microbiome treatment is designed to work. A patient has also been treated at City of Hope in the United States. Full video: https://lnkd.in/g7BDaAnG BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh

𝐊𝐥𝐞𝐢𝐧 𝐇𝐞𝐫𝐬𝐡 𝐏𝐫𝐞𝐜𝐢𝐬𝐢𝐨𝐧 𝐄𝐱𝐞𝐜𝐮𝐭𝐢𝐯𝐞 𝐒𝐞𝐚𝐫𝐜𝐡: While at #ASH24 this weekend, BiotechTV had a chance to connect with Klein Hersh 's Jeffrey Azarva, an expert in partnering with emerging biotech and global pharmaceutical companies on the recruitment of top physician talent in the oncology space. Seeking an exceptional new medical director, CMO, or Head of R&D? Connect with Jeff at https://lnkd.in/eumumEyR #sponsored

𝐅𝐫𝐨𝐦 𝐍𝐘𝐒𝐄: NewYorkBIO CEO Jennifer Hawks Bland discusses their annual event at the New York Stock Exchange and what is on the mind of companies today. Over 600 people registered for the event and took in company presentations and networking on the floor of the NYSE. Full video: https://lnkd.in/gJ_gJTzr BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | NYSE | Allucent | Klein Hersh